Tarsus Pharmaceuticals, Inc. (TARS) — SEC Filings
Tarsus Pharmaceuticals, Inc. (TARS) — 41 SEC filings. Latest: 10-Q (Nov 4, 2025). Includes 13 8-K, 13 SC 13G/A, 6 10-Q.
View Tarsus Pharmaceuticals, Inc. on SEC EDGAR
Overview
Tarsus Pharmaceuticals, Inc. (TARS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 4, 2025: Tarsus Pharmaceuticals, Inc. (TARS) reported significant revenue growth and a reduced net loss for the nine months ended September 30, 2025, driven by the successful commercialization of XDEMVY. Product sales, net, surged to $299.692 million for the nine months ended September 30, 2025, a substantia
Sentiment Summary
Across 41 filings, the sentiment breakdown is: 5 bullish, 34 neutral, 2 mixed. The dominant filing sentiment for Tarsus Pharmaceuticals, Inc. is neutral.
Filing Type Overview
Tarsus Pharmaceuticals, Inc. (TARS) has filed 6 10-Q, 13 8-K, 2 DEF 14A, 2 10-K, 13 SC 13G/A, 5 SC 13G with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (41)
Risk Profile
Risk Assessment: Of TARS's 21 recent filings, 1 were flagged as high-risk, 11 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $299,692,000 |
| Net Income | -$58,045,000 |
| EPS | N/A |
| Debt-to-Equity | 0.22 |
| Cash Position | $112,724,000 |
| Operating Margin | -21.0% |
| Total Assets | $534,561,000 |
| Total Debt | $72,281,000 |
Industry Context
The ophthalmic pharmaceutical market is highly competitive, with established players and emerging biotechs vying for market share. Tarsus is positioned in the niche of treating ocular surface diseases, with XDEMVY addressing a significant unmet need in Demodex blepharitis. Key trends include the development of novel drug delivery systems and treatments for chronic eye conditions.
Top Tags
institutional-ownership (5) · 10-Q (4) · corporate-governance (3) · biotech (3) · acquisition (3) · merger (3) · Tarsus Pharmaceuticals (3) · XDEMVY (2) · quarterly-report (2) · financials (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Product Sales, Net | $299.692M | Increased from $113.651M in 9M 2024, a 163.7% increase, driven by XDEMVY commercialization. |
| Net Loss | $58.045M | Reduced from $92.441M in 9M 2024, a 37.2% improvement, indicating progress towards profitability. |
| Cash and Cash Equivalents | $112.724M | Increased from $94.819M at December 31, 2024, bolstered by a March 2025 public offering. |
| Selling, General and Administrative Expenses | $296.641M | Increased from $168.280M in 9M 2024, reflecting significant investment in XDEMVY's commercial launch. |
| Outstanding Common Stock Shares | 42,449,105 | As of October 29, 2025, indicating potential dilution from recent offerings. |
| Product Revenue | $10.5M | for Q2 2025, up from $0.5M in Q2 2024, driven by XDEMVY launch |
| Selling, General, and Administrative Expenses | $30.0M | for Q2 2025, up from $16.0M in Q2 2024 due to commercialization |
| Research and Development Expenses | $18.2M | for Q2 2025, up from $14.1M in Q2 2024 |
| Reporting Period End Date | 2025-03-31 | Indicates the end of the fiscal quarter for which financial information is reported. |
| Reporting Period Start Date | 2025-01-01 | Indicates the beginning of the fiscal quarter for which financial information is reported. |
| Prior Year Quarter End Date | 2024-03-31 | Provides a comparative point for the current quarter's financial performance. |
| Prior Fiscal Year End Date | 2024-12-31 | Provides context for year-end financial position and comparison. |
| Filing Date | 20250428 | Date the DEF 14A was filed with the SEC. |
| Meeting Date | 20250612 | Date of the shareholder meeting for which this proxy statement is issued. |
| Acquisition Value | $1.1B | Total cash consideration for Tarsus Pharmaceuticals |
Forward-Looking Statements
- {"claim":"Tarsus Pharmaceuticals' stock may experience increased investor interest due to Morgan Stanley's disclosed stake.","entity":"Tarsus Pharmaceuticals, Inc.","targetDate":"Q1 2024","confidence":"medium"}
- {"claim":"Morgan Stanley will maintain a passive investment in Tarsus Pharmaceuticals for the foreseeable future.","entity":"Morgan Stanley","targetDate":"Q4 2024","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Tarsus Pharmaceuticals, Inc. (TARS)?
Tarsus Pharmaceuticals, Inc. has 41 recent SEC filings from Jan 2024 to Nov 2025, including 13 8-K, 13 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TARS filings?
Across 41 filings, the sentiment breakdown is: 5 bullish, 34 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Tarsus Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Tarsus Pharmaceuticals, Inc. (TARS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Tarsus Pharmaceuticals, Inc.?
Key financial highlights from Tarsus Pharmaceuticals, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for TARS?
The investment thesis for TARS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Tarsus Pharmaceuticals, Inc.?
Executive information for Tarsus Pharmaceuticals, Inc. is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Tarsus Pharmaceuticals, Inc. stock?
Of TARS's 21 assessed filings, 1 were flagged high-risk, 11 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Tarsus Pharmaceuticals, Inc.?
Recent forward-looking statements from Tarsus Pharmaceuticals, Inc. include guidance on {"claim":"Tarsus Pharmaceuticals' stock may experience increased investor interest due to Morgan Stanley's disclosed sta and 1 other predictions.